MODULATION OF SPINAL CORD NEUROPLASTICITY BY OPIOIDS
Project Number1K21DA000266-01
Contact PI/Project LeaderTERMAN, GREGORY W
Awardee OrganizationUNIVERSITY OF WASHINGTON
Description
Abstract Text
APPLICANT'S ABSTRACT: This application is a request for a Scientist
Development Award. This award is sought to enable my full time research
on the modulatory effects of opiates on spinal cord neurotransmission
and synaptic plasticity. These new research experiences under the
tutelage of my preceptor and additional consultants will equip me
technically and practically to move forward quickly to become an
independent researcher.
Long term potentiation (LTP), the best studied model, to date, of
synaptic plasticity within the CNS, involves a seemingly permanent
increase in neuronal excitation following repeated activation of
afferent input to that neuron and is thought to be the cellular
basis of learning. Recent clinical and behavioral evidence has
accumulated suggesting that much the same activity- dependent synaptic
changes can take place in neural systems involved in pain perception.
Intense painful stimuli can produce a central sensitization to
further noxious stimulation in both laboratory animals and man.
Behavioral pharmacologic studies of this sensitization suggest
numerous similarities to the neurochemistry of LTP, including its
reliance on activation of the NMDA class of glutamate receptors and
its modulation by certain opiates. The studies proposed here involve
the utilization of an in vitro spinal cord slice preparation to study
the opioid modulation of primary afferent dorsal horn synapses in
regions of the spinal cord known to be involved in nociceptive
processing. These studies stem directly from our findings in the
hippocampus that LTP induction can be blocked by kappa opioids. Initial
experiments using the neonatal rat transverse spinal cord slice will
focus on the actions of applied mu, kappa, and delta opioids in
modulating both stimulation-evoked neural excitation in lamina I of the
dorsal horn and activity-dependent plastic changes in this area. These
studies will use single cell extracellular recording techniques first and
will benefit from the in vitro preparation in enabling application of
known concentrations of agonists and antagonists to the site of action
and in allowing easy visualization of the recording electrode position.
Positive extracellular findings will be further evaluated using whole
cell voltage clamp techniques to study post-synaptic mechanisms of
action. Further, retrogradely transported fluorescent markers from
rostral spinothalamic tract lesions will be used to target specific
presumably nociceptive spinothalamic cell responses. The effects of
endogenous mu, delta and kappa opioids on spinal neurotransmission and
synaptic plasticity will then also be evaluated. Finally, these results
in neonatal spinal cord will be compared and contrasted to studies using
an adult spinal cord slice preparation. Thus, using an in vitro model and
a variety of electrophysiological techniques, we hope to provide insight
into the neurochemical mechanisms of primary afferent neurotransmission
and neuroplasticity and how mu, kappa, and delta opiates differentially
act to modulate these mechanisms in the adult and neonate. Such
information may ultimately lead to better pharmacological means of
managing and/or preventing certain acute and chronic pain states.
No Sub Projects information available for 1K21DA000266-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K21DA000266-01
Patents
No Patents information available for 1K21DA000266-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K21DA000266-01
Clinical Studies
No Clinical Studies information available for 1K21DA000266-01
News and More
Related News Releases
No news release information available for 1K21DA000266-01
History
No Historical information available for 1K21DA000266-01
Similar Projects
No Similar Projects information available for 1K21DA000266-01